LAX.SH
RPG LIFE SCIENCES LTD·PHARMACEUTICALS 66.37·Pharmaceuticals & Biotechnology Companies
Price
2,780.2
-0.62%52W Range
Market Cap
₹4,598.18 Cr
Traded: ₹2.52 Cr (0.05%) 0.0x
Free Float: ₹810.20 Cr (0.31% of FF traded)
Volume · 60D trend
9.18 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | -- | -- | -- | -- | -- | -- |
| Return | +25.0% | +36.0% | +40.0% | +10.0% | -- | Stable |
| Sales | -- | -- | -- | -- | +8.0% | -- |
| Profit | -- | -- | -- | -- | -5.0% | -- |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | |
|---|---|---|---|---|---|---|---|
| Sales | 196 | 177 | 180 | 182 | 169 | 143 | 173 |
| Expenses | 152 | 144 | 140 | 143 | 133 | 118 | 124 |
| Operating Profit | 43 | 33 | 40 | 39 | 35 | 25 | 49 |
| Other Income | 5 | 14 | -5 | 16 | 5 | 115 | 3 |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 6 | 6 | 5 | 5 | 5 | 5 | 5 |
| Profit Before Tax | 41 | 40 | 29 | 49 | 35 | 135 | 47 |
| Tax % | 26.0% | 26.0% | 24.0% | 25.0% | 26.0% | 13.0% | 26.0% |
| Net Profit | 31 | 30 | 22 | 37 | 26 | 117 | 35 |
| Exceptional Items | -- | 1 | -8 | 11 | -- | 110 | 0 |
| EPS (Rs) | 18.6 | 18.1 | 13.4 | 22.3 | 15.9 | 71.0 | 21.1 |
| Sales Growth (YoY) | -- | 23.6% | 4.2% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -- | -1.7% | -1.1% | 27.3% | -- | -17.3% | -- |
| OP Growth (YoY) | 22.9% | 32.0% | -18.4% | -- | -- | -- | -- |
| OP Growth (QoQ) | 30.3% | -17.5% | 2.6% | 11.4% | 40.0% | -49.0% | -- |
| Profit Growth (YoY) | -- | 33.7% | -18.3% | -- | -- | -- | -- |
| EPS Growth (YoY) | -- | -74.5% | -36.6% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 35.1% | -40.0% | -68.6% | -- | 235.9% | -- |
| OP Margin | -- | 18.6% | 22.2% | 21.4% | -- | 17.5% | 28.3% |
| Net Margin | -- | 16.9% | 12.2% | 20.3% | -- | 81.8% | 20.2% |
| Material Cost % | -- | 34.3% | 36.0% | 36.6% | -- | 34.0% | 32.5% |
| Employee Cost % | -- | 20.5% | 19.6% | 19.9% | -- | 22.1% | 16.6% |
| P/S | 6.26 | 7.01 | -- | -- | -- | -- | -- |
| P/E | 38.43 | 23.17 | -- | -- | -- | -- | -- |
| P/B | 7.60 | 7.90 | -- | -- | -- | -- | -- |
Exchange Filings
50RPG Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve unaudited financial results ....
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018
Newspaper advertisement in respect to Special window opened for lodgment of transfer and dematerialization request(s).
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Clarus Capital I, Others
Intimation of Analysts/Institutional Investors Meet
Update on completion of BTA execution by RPG Active Pharma Limited with Raghava Life Sciences Private Limited
update on Investment and Shareholders Agreement entered on July 29, 2026, subsidiary of the company allotted securities to the Investors.
Update on Analyst/Institutional call
Intimation of Investor meet dial in details
Schedule of Investors Meet
Investors Presentation
Press Release
Intimation of execution of Business Transfer Agreement by RPG Active Pharma Limited (WOS) with Raghava Life Sciences Private Limited for Acquisition of API Business.
Outcome of Board Meeting
Cancellation of Investor meet
The Company has informed about the Schedule of Analyst/Institutional Investors Meet
The Company has informed about the Schedule of Analyst/Institutional Investors Meet
Completion of transactions in API Business Transfer Agreement with RPG Active Pharma Limited.
RPG Life Sciences Limited has informed the Exchange about the Further investment in RPG Active Pharma Limited
Resignation of Senior Management Personnel
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the details of the Analyst/Institutional ....
Unaudited consolidated and standalone Financial Results for quarter ended June 2026
Completion of term of Ms. Zahabiya Khorakiwala
19th AGM Proceedings
Voting Results along with a copy of Scrutinizer''s Report
RPG Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2026 ,inter alia, to consider and approve Pursuant to the provisions ....
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018
Press release with respect to Naprosyn ES Launch
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, please find enclosed the copy of Notice of 19th AGM published in today''s newspaper in Business Standard (English) and Mumbai ....
Intimation under regulation 30 regarding letter dispatched to those Shareholders whose email addresses are not registered with Company/RTA/ NSDL / CDSL, stating the web link where the Annual ....
Business Responsibility and Sustainability Report 2026
Notice of 19th Annual General Meeting
Annual Report
Closure of Trading Window
Newspaper publication
Record date for determining members eligible to receive dividend for the financial year 2025-26.
The Exchange has sought clarification from RPG Life Sciences Ltd on June 12, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.
Clarification for Volume Movement Letter
Intimation to shareholders holding shares in physical form for furnishing KYC details
Communication to shareholders - Intimation on dividend Taxation provisions
Investor Presentation
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Annual Secretarial Compliance Report for the year ended March 31, 2026.
The Company informed the Exchange about Transcript of Earnings Call.
The Company has informed about the recording of Earnings Call.
Newspaper Publication
Investor Presentation
Press Release
Amendment to the Code
Financial Results for Quarter and Yer ended on March 31, 2026
Annual Reports
15Credit Ratings
6Concalls
32Jan 2026
31 Jan 2026Oct 2025
31 Oct 2025Jul 2025
31 Jul 2025Jun 2025
30 Jun 2025Apr 2025
30 Apr 2025Nov 2024
30 Nov 2024Sep 2024
30 Sept 2024Jul 2024
31 Jul 2024Jun 2024
30 Jun 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Oct 2023
31 Oct 2023Jul 2023
31 Jul 2023Jun 2023
30 Jun 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Feb 2023
28 Feb 2023Oct 2022
31 Oct 2022Sep 2022
30 Sept 2022Aug 2022
31 Aug 2022May 2022
31 May 2022Feb 2022
28 Feb 2022Jan 2022
31 Jan 2022Nov 2021
30 Nov 2021Aug 2021
31 Aug 2021Jun 2021
30 Jun 2021Jun 2019
30 Jun 2019Jun 2018
30 Jun 2018Nov 2017
30 Nov 2017Jun 2017
30 Jun 2017Nov 2016
30 Nov 2016Jun 2016
30 Jun 2016Held by ETFs
1 ETFs hold RPGLIFE · sorted by weight
Held by Mutual Funds
2 schemes hold RPGLIFE · sorted by weight